CAPR News and Press, Capricor Therapeutics Inc.

2026-07-01 13:51:49 ET More on Hims & Hers Health, Moderna, etc. Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial Hims & Hers: Can Fundamentals Really Support This Rebound Rally? (Downgrade) Advancements in mRNA Technology, Cli...

–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology compan...

2026-06-26 09:59:25 ET More on Capricor Therapeutics, Inc. Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis Capricor Therapeutics, Inc....

Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE study PUL 2.0 year-over-year decline attenuated to approximately 1 point Findings to be presented alongside previously reported HOPE-3 Phase 3 results, which met its primary and key seconda...

2026-06-24 12:38:33 ET More on Regenxbio, uniQure, etc. Moderna: Flu Vaccine Progress Is Only Part Of The Story Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade) Moderna: The Comeback Is Now In Full Swing uniQure prices upsized $225M public offe...

2026-06-24 08:01:10 ET More on healthcare stocks IXJ: Healthcare Sector Dashboard For June IHI: Pressured Consumers, Unclear Healthcare Policy, Weak Price Action AI Revolutionizing Biopharma: Faster, Better, Cheaper Weekly ETFs: Five of 11 sectors record...

2026-06-18 15:28:24 ET The last time I spoke about Biohaven ( BHVN ) it was with a Seeking Alpha article entitled " Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 ." With respect to this article, I mentioned that the company had achieved a comp...

2026-06-17 14:35:09 ET More on Regenxbio, Capricor Therapeutics, Inc., etc. Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Replimune: Modeling The Coin Flip Of FDA Approval Capricor: I Rate It A B...

2026-06-10 13:52:11 ET Capricor Therapeutics, Inc. (CAPR) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:00 AM EDT... Read the full article on Seeking Alpha For further details see: Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47...

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences. ...